Pneumonia vaccine

Pneumonia vaccine

Pneumonia vaccine provides protection against pneumococcal disease caused by a bacterium called Streptococcus Pneumoniae.

1. Who is eligible for Pneumonia Vaccine?

Centers for Disease Control and Prevention suggested Pneumococcal vaccination for all children younger than 2 years old and all adults 65 years or older. In some conditions, other children and adults should also get pneumococcal vaccines. Below answers more info is given .

2.How effective is the Pneumonia Vaccine?

When should pneumococcal vaccine be given?
Pneumonia Vaccine  is 60% to 70% effective in preventing invasive disease caused by serotypes in the vaccine. PPSV23 shows reduced effectiveness among immunocompromised persons; however, CDC recommends PPSV23 for these groups because of their increased risk of invasive pneumococcal disease (IPD).

3.What is the difference between Prevnar 13 and 23 ?

The main difference between Prevnar 13 and Pneumovax 23 is how many different types of bacteria they target. Prevnar 13 protects against 13 types of pneumococcal bacteria while  Pneumovax 23 protects against 23 types of pneumococcal bacteria.

4.Pneumonia Vaccine how often ?

Pneumonia Vaccine dose depends on age and individual current immunization status. Centers for Disease Control and Prevention support two Pneumococcal vaccines for all adults and 65 plus persons should receive one dose of PCV13 first, and followed by another one dose of PPSV23 after a year at least.

5.Pneumonia Vaccine cost

Pneumonia Vaccine cost  is prohibitive, being Rs. 1600/dose for
10-valent vaccine and around Rs. 3200/dose for the 13-valent vaccine

6. Pneumonia Vaccine side effects

Soreness at the injection site and fever.

7. Pneumonia Vaccine how long does it last?

Pneumonia vaccines help prevent invasive pneumococcal diseases. However, it depends on the age and overall health and immunization status of a person .

8. Pneumonia Vaccine name

Pneumococcal Polysaccharide Vaccine (PPSV)
Pneumococcal conjugate vaccine (PCV) PCV10 AND
Available as ready to use liquid formations

9. Pneumonia Vaccine schedule

PCV 10/13 : 3 doses at 6, 10 and 14 weeks
Booster 15 to 18 months
PPSV: Above 2 years of age and reserved for high risk cases only

10.Catch up Immunization

a) For children who are not completely immunized with vaccines required for their age, administer one dose of PCV 13 or PCV 10 to all healthy children 24 to 59 months .
b) For PCV 13 the vaccination schedule is as follows 6;12 months two doses in an interval of 4 weeks and one booster dose ; 12-23 months,two doses of interval of 8 weeks >= 24 months: single dose
c) For PCV10 the vaccination schedule as follows: 6-12 months
two doses at an interval of 4 weeks and one booster dose; 12 months to 5 years two doses an interval of 8 weeks.
d) Above 50 years, PCV 13 is administered as single dose.

11.Store of Pneumonia Vaccine
2 Celsius and +8 Celsius
Do not freeze

Dose and Route of Administration

0.5 mL IM in the anterolateral of thigh or deltoid

Type of Vaccine

(a) Killed inactivated, conjugate ( Pneumococcal Polysaccharide bound to be carrier protein; does not contain any live bacteria
(b) Killed inactivated Polysaccharide unconjugated vaccines (PPSV)

Special Comments

a) Interchangeability between PCV10 and PCV13 has not been documented.
However, if it is not possible to complete the series with the same type of Vaccine, the other PCV product can be used.
b) Based on the evidence of both PCV10 and PCV13 offer almost comparable safety and efficacy, particularly for mass use. Nevertheless, the choice of the formulation will depend on the prevalence of vaccine stereotypes in the country, as well as vaccine supply and pricing.
c) Conjugate vaccines eradicate nasopharyngeal carriage, this gives herd immunity also.

Pneumococcal Polysaccharide Vaccine (PPSV)

The minimum age to administer PPSV is 2 years

•This vaccine is not recommended for routine use in healthy individuals It is recommended only for the vaccination of individuals with certain high-risk conditions.
• PPSV vaccines should be administered at least 8 weeks after the last dose of PCV in children aged 2 years or older with certain underlying medical conditions, such as anatomic or functional asplenia including sickle cell disease), HIV infection, cochlear implant or cerebrospinal fluid leak.
•An additional dose of PPSV should be administered after 5 years in children with anatomic functional asplenia or those suffering from an immunocompromising condition
• PPSV should never be used alone for prevention of pneumococcal diseases in high-risk individuals
• Children aged 24 through 71 months with the following medical conditions for which PPV23 and PCV13 are indicated
• Immunocompetent children with chronic heart diseases (particularly cyanotic congenital heart disease and cardiac failure), chronic lung diseases including asthma, if treated with high-dose oral corticosteroid therapy diabetes mellitus, cerebrospinal fluid leak, or cochlear implant
• Children with anatomic or functional asplenia (including sickle cell disease and other hemoglobinopathies congenital or acquired asplenia, or splenic dysfunction)

•Immune weak Children conditions, such as chronic renal failure, HIV infection,, and nephrotic syndrome, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemia, lymphoma, and Hodgkin disease, solid-organ transplantation and congenital immunodeficiency.
Adults at Risk for Pneumococcal Disease

• Adults aged 65 years and above are at an increased risk for pneumococcal disease
• Some adults aged 19 through 84 years are also at an increased risk for pneumococcal disease, including those . 
With chronic illnesses (chronic heart, liver, kidney, or lung [including chronic obstructive lung disease, emphysema, and asthma disease, diabetes, or alcoholism)
• With conditions that weaken the immune system {HIV AIDS cancer, or damaged/absent spleen)
• With cochlear implants or CSF leak escape of the fluid that surrounds the brain and spinal cord)
• Who smoke cigarettes

Dosage and Route of Administration (in at Risk Cases)
• 05 PCV13 injection administered IM followed by 05 mL PPSV after 8 weeks • PPSV may be repeated once after 5 years if required